Has Brian Zelickson, MD received payments from drug or device companies?

Yes. Drug and device makers reported $13,694 in general payments to Brian Zelickson, MD across 27 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Brian Zelickson, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Brian Zelickson, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Brian Zelickson, MD

Dermatology · Minneapolis, MNNPI 1336195148

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (55.1%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. AbbVie accounts for 63.7% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2021 at $5,012 and has fallen 96.7% since, to $165 in 2025. Among dermatology clinicians in MN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$13,694in general payments, 2019–2025

Across 27 payments — averaging $507.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$9K
Solta Medical, A Division Of Bausch Health US, LLC$4K
Edwards Lifesciences$510
Revance Therapeutics, Inc.$235
Merz North America, Inc.$78
Johnson & Johnson$53
plus $159 from 7 others

$40,041in research payments, 2019–2025

Across 12 payments — averaging $3336.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

AbbVie$13K
Zerigo Health, Inc.$12K
E.r. Squibb & Sons, L.L.C.$8K
Merz North America, Inc.$7K

What the payments were for

Consulting fees$7,55255%
Speaking & faculty fees$4,99436%
Travel & lodging$4073%
Food & beverage$6695%
Education$731%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	6	$8,721
Solta Medical, A Division Of Bausch Health US, LLC	2	$3,939
Edwards Lifesciences	2	$510
Revance Therapeutics, Inc.	3	$235
Merz North America, Inc.	2	$78
Johnson & Johnson	3	$53
Davol Inc.	1	$43
Amgen	2	$30
Strata Skin Sciences, Inc.	2	$21
Incyte Corporation	1	$18
E.r. Squibb & Sons, L.L.C.	1	$16
Sanofi	1	$15
LEO Pharma Inc.	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

BOTOX COSMETIC$3,727

How this compares

$13,694 in reported general payments places this provider in the 90th percentile of 273 dermatology providers in Minnesota.

See all dermatology providers in Minnesota →

Medicare billing

Part B allowed, 2024

$144,860

Medicare patients

803

Services billed

2,853

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Metronidazole	52	$3,573
Ivermectin	11	$2,938
Ketoconazole	101	$1,743
Clindamycin Phosphate	33	$1,166
ValacyclovirValacyclovir Hcl	80	$760
Tretinoin	22	$752
Mometasone Furoate	33	$747
Clobetasol Propionate	30	$714
Fluocinonide	29	$657
Desonide	30	$587
Triamcinolone Acetonide	52	$503
Mupirocin	28	$182
Cephalexin	17	$84

Paid to pharmacies, not to this prescriber.

Other dermatology in Minneapolis

Margareth Pierre-LouisMinneapolis$439K
Maria HordinskyMinneapolis$85K
Brittney SchultzMinneapolis$52K
David PearsonMinneapolis$46K
Noah GoldfarbMinneapolis$30K
Paul BigliardiMinneapolis$21K
Sara HylwaMinneapolis$5K
Timothy AllenMinneapolis$3K
Kimberly BohjanenMinneapolis$2K
Jaime DavisMinneapolis$1K

See the full list for Minnesota →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →